Mahamaya Lifesciences Limited submitted its audited financial results for the financial year ended March 31, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance Highlights (in ₹ Lakhs)
Annual Results (FY26 vs FY25):
- Revenue From Operations: ₹3,288.73 lakhs (FY26) vs ₹2,641.49 lakhs (FY25) - increase of 24.50%
- EBITDA: ₹342.59 lakhs (FY26) vs ₹258.33 lakhs (FY25) - increase of 32.06%
- EBITDA Margin: 10.42% (FY26) vs 9.82% (FY25) - improvement of 60 basis points
- PAT: ₹165.23 lakhs (FY26) vs ₹128.12 lakhs (FY25) - increase of 28.97%
- PAT Margin: 5.02% (FY26) vs 4.85% (FY25) - improvement of 17 basis points
- EPS (Diluted): ₹8.33 (FY26) vs ₹7.52 (FY25) - increase of 10.77%
Half-Yearly Performance (H2 FY26):
- Revenue From Operations: ₹1,658.09 lakhs
- EBITDA: ₹217.90 lakhs
- EBITDA Margin: 10.79%
Management Commentary
Mr. Prashant Krishnamurthy, Executive Director, stated that FY26 was a year of strong operational and financial performance. The company noted that profitability was impacted by certain accounting and listing-related adjustments aggregating to approximately ₹411 lakhs, comprising:
- Unrealized forex loss: ₹264.16 lakhs
- Exchange difference: ₹125.25 lakhs
- Listing-related expenses: ₹21.57 lakhs
Despite these impacts, the company delivered healthy PAT of ₹165.23 lakhs, demonstrating business resilience and strong underlying momentum.
Business Outlook
The company remains focused on expanding its sustainable and biological crop care portfolio while strengthening its presence in domestic and export markets for long-term growth. The company has a comprehensive portfolio of over 50 products across key categories and operates a modern Dahej facility equipped for large-scale production and R&D innovation.